Stock 4171 GENEREACH BIOTECHNOLOGY CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GeneReach Biotechnology Corp.

Equities

4171

TW0004171004

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
31.95 TWD +0.47% Intraday chart for GeneReach Biotechnology Corp. +5.10% -19.01%
Mar. 28 GeneReach Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GeneReach Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,326 2,740 5,256 3,794 3,034 2,267
Enterprise Value (EV) 1 1,541 2,638 5,131 3,501 2,675 2,013
P/E ratio 49.3 x 34.8 x 20.5 x 10.3 x 14.1 x -13.6 x
Yield - - 2.73% 5.51% 2.27% -
Capitalization / Revenue 7.07 x 7.49 x 6.13 x 3.75 x 4.04 x 10.1 x
EV / Revenue 8.22 x 7.21 x 5.99 x 3.46 x 3.57 x 8.93 x
EV / EBITDA 63 x 19.8 x 12.9 x 6.59 x 9.14 x -11.5 x
EV / FCF -11.9 x 12.2 x 110 x 10.6 x 10.2 x 89.2 x
FCF Yield -8.38% 8.23% 0.91% 9.46% 9.83% 1.12%
Price to Book 4.63 x 4.93 x 6.47 x 3.61 x 2.84 x 2.72 x
Nbr of stocks (in thousands) 48,610 57,457 57,457 57,457 57,458 57,458
Reference price 2 27.27 47.68 91.48 66.04 52.80 39.45
Announcement Date 3/26/19 3/30/20 3/30/21 3/24/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 187.4 365.8 857 1,012 750 225.5
EBITDA 1 24.46 133 398.4 531.3 292.8 -174.3
EBIT 1 11.38 111.9 355.4 482.4 241.3 -229.3
Operating Margin 6.07% 30.6% 41.47% 47.66% 32.18% -101.7%
Earnings before Tax (EBT) 1 28.83 105.5 338.9 469.4 272.4 -218.3
Net income 1 28.57 77.18 257.3 376.6 221.3 -166.3
Net margin 15.24% 21.1% 30.02% 37.21% 29.51% -73.75%
EPS 2 0.5526 1.370 4.472 6.437 3.738 -2.894
Free Cash Flow 1 -129.1 217 46.48 331.2 262.9 22.55
FCF margin -68.89% 59.34% 5.42% 32.73% 35.05% 10%
FCF Conversion (EBITDA) - 163.21% 11.67% 62.35% 89.79% -
FCF Conversion (Net income) - 281.22% 18.06% 87.95% 118.78% -
Dividend per Share - - 2.500 3.636 1.200 -
Announcement Date 3/26/19 3/30/20 3/30/21 3/24/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 215 - - - - -
Net Cash position 1 - 102 126 294 359 254
Leverage (Debt/EBITDA) 8.8 x - - - - -
Free Cash Flow 1 -129 217 46.5 331 263 22.6
ROE (net income / shareholders' equity) 10.6% 20.7% 36.4% 38.1% 19.9% -17.3%
ROA (Net income/ Total Assets) 1.1% 9.62% 22.2% 20.6% 9.12% -10.2%
Assets 1 2,605 802.4 1,159 1,827 2,426 1,623
Book Value Per Share 2 5.890 9.670 14.10 18.30 18.60 14.50
Cash Flow per Share 2 2.030 3.080 5.460 11.50 13.00 3.770
Capex 1 2.31 13.5 62.2 19.6 49.9 23.5
Capex / Sales 1.23% 3.7% 7.26% 1.93% 6.65% 10.44%
Announcement Date 3/26/19 3/30/20 3/30/21 3/24/22 3/30/23 3/28/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. 4171 Stock
  4. Financials GeneReach Biotechnology Corp.